Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoHealth (GOCO) Minority Interest (2020 - 2025)

GoHealth's Minority Interest history spans 6 years, with the latest figure at -$75.1 million for Q3 2025.

  • For Q3 2025, Minority Interest fell 156.36% year-over-year to -$75.1 million; the TTM value through Sep 2025 reached -$75.1 million, down 156.36%, while the annual FY2024 figure was $163.6 million, 6.32% down from the prior year.
  • Minority Interest for Q3 2025 was -$75.1 million at GoHealth, down from $87.3 million in the prior quarter.
  • Across five years, Minority Interest topped out at $951.9 million in Q1 2021 and bottomed at -$75.1 million in Q3 2025.
  • The 5-year median for Minority Interest is $210.8 million (2023), against an average of $333.0 million.
  • The largest annual shift saw Minority Interest skyrocketed 1172680.43% in 2021 before it plummeted 156.36% in 2025.
  • A 5-year view of Minority Interest shows it stood at $539.4 million in 2021, then crashed by 49.27% to $273.6 million in 2022, then crashed by 36.18% to $174.6 million in 2023, then dropped by 6.32% to $163.6 million in 2024, then plummeted by 145.89% to -$75.1 million in 2025.
  • Per Business Quant, the three most recent readings for GOCO's Minority Interest are -$75.1 million (Q3 2025), $87.3 million (Q2 2025), and $155.5 million (Q1 2025).